Luigi Grasso

2.7k total citations
68 papers, 2.2k citations indexed

About

Luigi Grasso is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Luigi Grasso has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 28 papers in Oncology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Luigi Grasso's work include Monoclonal and Polyclonal Antibodies Research (19 papers), Cancer Research and Treatments (10 papers) and Glycosylation and Glycoproteins Research (8 papers). Luigi Grasso is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), Cancer Research and Treatments (10 papers) and Glycosylation and Glycoproteins Research (8 papers). Luigi Grasso collaborates with scholars based in United States, Italy and Belgium. Luigi Grasso's co-authors include Nicholas C. Nicolaides, Philip M. Sass, W E Mercer, Katherine A. Rybinski, Wolfgang Ebel, J. Bradford Kline, Earl F. Albone, Craig D. McClain, Albert Deisseroth and Ying Cha and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Luigi Grasso

67 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luigi Grasso United States	25	837	805	440	422	254	68	2.2k
Craig D. Peacock United States	22	1.1k 1.3×	1.2k 1.5×	299 0.7×	352 0.8×	110 0.4×	47	2.3k
Nils Cordes Germany	40	1.9k 2.2×	2.2k 2.7×	615 1.4×	365 0.9×	431 1.7×	132	4.5k
Kerstin Borgmann Germany	32	1.2k 1.4×	1.8k 2.2×	497 1.1×	165 0.4×	504 2.0×	85	2.7k
Iris Eke Germany	27	886 1.1×	1.0k 1.3×	374 0.8×	173 0.4×	282 1.1×	52	2.1k
Graeme J. Dougherty United States	18	472 0.6×	741 0.9×	304 0.7×	603 1.4×	355 1.4×	44	2.0k
Nicholas H. A. Terry United States	28	647 0.8×	854 1.1×	559 1.3×	146 0.3×	450 1.8×	90	2.3k
Siham Sabri Canada	26	603 0.7×	569 0.7×	337 0.8×	176 0.4×	375 1.5×	57	2.0k
Sean P. Pitroda United States	33	1.8k 2.1×	1.1k 1.4×	1.0k 2.3×	933 2.2×	485 1.9×	94	3.4k
Agamemnon A. Epenetos United Kingdom	30	665 0.8×	1.1k 1.3×	250 0.6×	407 1.0×	1.4k 5.5×	84	2.5k
Mikhail Doubrovin United States	26	1.2k 1.4×	1.4k 1.8×	261 0.6×	548 1.3×	547 2.2×	65	3.3k

Countries citing papers authored by Luigi Grasso

Since Specialization

Citations

This map shows the geographic impact of Luigi Grasso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Grasso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Grasso more than expected).

Fields of papers citing papers by Luigi Grasso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Grasso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Grasso. The network helps show where Luigi Grasso may publish in the future.

Co-authorship network of co-authors of Luigi Grasso

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Grasso. A scholar is included among the top collaborators of Luigi Grasso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Grasso. Luigi Grasso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nicolaides, Nicholas C., J. Bradford Kline, & Luigi Grasso. (2023). NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects. PLoS ONE. 18(5). e0285161–e0285161. 8 indexed citations

Grasso, Luigi, et al.. (2023). NAV‐003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors. European Journal of Immunology. 53(8). e2250309–e2250309. 2 indexed citations

Martino, Fabio Di, Sandro Barone, Federica Galante, et al.. (2022). A NEW MODEL OF GAS CHAMBER FOR UHDR RANGE. Physica Medica. 94. S82–S82. 2 indexed citations

Martino, Fabio Di, Salvatore Barone, Massimo Di Francesco, et al.. (2022). FLASH in the Clinic Track (Oral Presentations) A NOVEL METHOD FOR DETERMINING IC SATURATION FACTOR (UP TO 0.5 GY/P FOR ADV. MARKUS). Physica Medica. 94. S43–S43. 1 indexed citations

Grasso, Luigi, et al.. (2021). Block‑Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125‑mediated immunosuppression. Oncology Letters. 23(1). 2–2. 2 indexed citations

Martino, Fabio Di, Salvatore Barone, Silvia De Stefano, et al.. (2020). FLASH Radiotherapy With Electrons: Issues Related to the Production, Monitoring, and Dosimetric Characterization of the Beam. Frontiers in Physics. 8. 82 indexed citations

Felici, G., Salvatore Barone, Silvia De Stefano, et al.. (2020). Transforming an IORT Linac Into a FLASH Research Machine: Procedure and Dosimetric Characterization. Frontiers in Physics. 8. 35 indexed citations

Cheng, Xin, Jing Li, Keigo Tanaka, et al.. (2018). MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Molecular Cancer Therapeutics. 17(12). 2665–2675. 75 indexed citations

Rybinski, Katherine A., Xin Cheng, Earl F. Albone, et al.. (2018). Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts. Molecular Cancer Therapeutics. 17(1_Supplement). B115–B115. 1 indexed citations

10.

Wang, Wenquan, Elizabeth B. Somers, J. Bradford Kline, et al.. (2017). FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. Cytogenetic and Genome Research. 152(4). 169–179. 16 indexed citations

11.

O’Shannessy, Daniel J., Charles Schweizer, Wenquan Wang, et al.. (2017). Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics. 109(3-4). 251–257. 15 indexed citations

12.

Kim, Hee-Jung, Zhengsheng Yao, Lawrence P. Szajek, et al.. (2015). Tumor and organ uptake of 64Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies. Nuclear Medicine and Biology. 42(11). 880–886. 12 indexed citations

13.

Nicolaides, Nicholas C., et al.. (2014). Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy. Frontiers in Oncology. 4. 141–141. 22 indexed citations

14.

Li, Chunsheng, Ann‐Marie Chacko, Kosei Hasegawa, et al.. (2014). Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology & Therapy. 15(4). 443–451. 21 indexed citations

15.

Lin, Jianmin, Jared Spidel, Katherine A. Rybinski, et al.. (2013). The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biology & Therapy. 14(11). 1032–1038. 43 indexed citations

16.

Tomkowicz, Brian, Katherine A. Rybinski, Philip M. Sass, et al.. (2010). Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biology & Therapy. 9(11). 908–915. 68 indexed citations

17.

Nicolaides, Nicholas C., Philip M. Sass, & Luigi Grasso. (2010). Advances in targeted therapeutic agents. Expert Opinion on Drug Discovery. 5(11). 1123–1140. 20 indexed citations

18.

Bell‐McGuinn, Katherine M., Jason Konner, Neeta Pandit‐Taskar, et al.. (2007). A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer. Journal of Clinical Oncology. 25(18_suppl). 5553–5553. 1 indexed citations

19.

Nicolaides, Nicholas C., Wolfgang Ebel, Qimin Chao, et al.. (2005). Morphogenics as a Tool for Target Discovery and Drug Development. Annals of the New York Academy of Sciences. 1059(1). 86–96. 11 indexed citations

20.

Grasso, Luigi & W E Mercer. (1997). Pathways of p53-Dependent Apoptosis. Vitamins and hormones. 53. 139–173. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact